✓ Medically reviewed by · Last reviewed: May 2026
Pharmacy Researcher · 8 years experience
Pharmacy researcher with 8 years reviewing clinical drug information, generic formulation equivalence, and international pharmaceutical standards. Focuses on patient-facing accuracy in medication education.
Key takeaways
- Different receptor architectures. Mazdutide = GLP-1 + glucagon (dual agonist). Retatrutide = GLP-1 + GIP + glucagon (triple agonist).
- Both have glucagon arms. Retatrutide adds the GIP arm on top, producing the deeper Phase 2 effect-size readout.
- Geographically distinct development pathways. Mazdutide is China-led (Innovent / Lilly licensing); retatrutide is Lilly-direct in the global TRIUMPH program.
- Trial readouts: Mazdutide -11.1% at 24 wk (6 mg). Retatrutide -24.2% at 48 wk (12 mg). Direct comparison limited by different timeframes.
- This guide compares mechanism, trial data, regulatory pathway, and research applicability.
Mazdutide vs Retatrutide: Dual GLP-1 / Glucagon vs Triple Agonist Compared
Both molecules sit at the frontier of incretin pharmacology — both have glucagon-receptor activity (the differentiating mechanism arm vs GLP-1 monoagonism), and both are in late-stage clinical development. The differentiator is whether GIP is also activated. Mazdutide skips the GIP arm; retatrutide retains it. This guide covers what that single architectural difference produces in trial data and research applicability.
Quick verdict
- Maximum effect size research: Retatrutide (triple agonist; deeper readouts).
- GLP-1 / glucagon dual-agonist mechanism (no GIP arm): Mazdutide or Survodutide.
- Asian / Chinese-population research: Mazdutide (developed primarily in Chinese clinical trials).
- GIP-arm contribution research: Compare mazdutide (no GIP) with retatrutide (with GIP) directly — the contrast isolates the GIP arm.
Mechanism: with or without GIP
Both molecules share the GLP-1 and glucagon arms. GLP-1 agonism drives appetite suppression and slowed gastric emptying. Glucagon agonism adds direct hepatic energy expenditure and improves hepatic-lipid endpoints (favourable for MASH / fatty-liver research). The combination produces deeper weight loss than GLP-1 monoagonism.
Where the two diverge: retatrutide adds GIP agonism on top of the GLP-1 + glucagon foundation. GIP activates the enteroinsular axis and appears to deepen satiety while attenuating GI side effects. Mazdutide skips the GIP arm entirely.
The clean research question this enables: “What does the GIP arm specifically contribute, controlling for GLP-1 and glucagon?” Direct comparison of mazdutide and retatrutide at matched doses and matched receptor occupancy on the GLP-1 and glucagon arms would isolate the GIP-arm contribution — a research design directly relevant to next-generation incretin development.
Trial data side by side
| Trial | Molecule | Mean weight loss | Duration | Top dose |
|---|---|---|---|---|
| Phase 2 (Innovent, Chinese subjects) | Mazdutide | -11.1% | 24 wk | 6 mg weekly |
| Phase 2 (NEJM 2023) | Retatrutide | -24.2% | 48 wk | 12 mg weekly |
Caveat: direct comparison is limited by different trial durations (24 wk vs 48 wk) and different study populations (Chinese subjects in the mazdutide Phase 2; multi-region in retatrutide’s Phase 2). At extrapolated 48-week timeframes the mazdutide readout would likely be deeper than the 24-wk readout, but the matched-window data does not yet exist.
Comparison table
| Property | Mazdutide | Retatrutide |
|---|---|---|
| Receptor arms | GLP-1 + glucagon (dual) | GLP-1 + GIP + glucagon (triple) |
| Developer | Innovent Biologics / Eli Lilly licensing | Eli Lilly (direct) |
| CAS | 2259147-25-2 | 2381089-83-2 |
| MW | ~4860 | ~4731 |
| Phase 2 weight loss (max dose) | -11.1% (24 wk, 6 mg) | -24.2% (48 wk, 12 mg) |
| Phase 3 program | DREAMS (China) | TRIUMPH (global) |
| Regulatory pathway | NMPA (China) lead, possible FDA/EMA later | FDA/EMA global |
| Half-life | ~8 days | ~6 days |
| Hepatic / MASH activity | Substantial (glucagon arm) | Substantial (glucagon arm) |
Which to pick (research-protocol logic)
- Maximum effect-size research: Retatrutide. Deepest published readout in any single incretin compound.
- GLP-1 / glucagon dual-agonist mechanism research (no GIP confound): Mazdutide or survodutide. The two cleanest dual-agonist options without the GIP arm.
- GIP-arm contribution research: Mazdutide vs retatrutide head-to-head in the same protocol — the contrast isolates GIP’s contribution.
- Asian-population research: Mazdutide (developed primarily in Chinese clinical trials).
- MASH / fatty-liver research: Either molecule (both have glucagon arms with documented hepatic-lipid effects).
Safety and regulatory status
Both compounds are in clinical development without FDA / EMA / MHRA approval. Mazdutide is approaching NMPA (China) regulatory review through the DREAMS Phase 3 program; retatrutide is in the global TRIUMPH Phase 3 program. The research-grade lyophilized peptides are sold for in-vitro laboratory research and analytical reference use only. Class-level safety considerations include GI side effects, gallstone risk with rapid weight loss, hypoglycaemia risk, and the rare pancreatitis signal seen across the incretin class. None of this is medical advice.
FAQ
How is mazdutide different from survodutide?
Both are GLP-1 / glucagon dual agonists. Different developers (Innovent for mazdutide, Boehringer Ingelheim for survodutide). Different regulatory pathways (NMPA-led for mazdutide, FDA/EMA-led for survodutide). Phase 2 effect sizes are broadly similar (-11.1% at 24 wk for mazdutide vs -18.7% at 46 wk for survodutide), with the mazdutide readout limited by the shorter trial duration. See: Survodutide vs Tirzepatide.
Will mazdutide get FDA approval?
Unclear. The development pathway has been NMPA (China) lead, with global expansion possible but not yet committed. The licensing structure (Innovent has Chinese rights; Eli Lilly may exercise global development rights) could route the molecule into the FDA pathway, but as of catalogue date this is speculative.
What does the GIP arm contribute that mazdutide doesn’t have?
Two things based on the published research: (1) deeper appetite suppression at matched receptor activation levels on the GLP-1 arm; (2) potentially attenuated GI side effects relative to pure GLP-1 monoagonism. The retatrutide-vs-mazdutide head-to-head comparison would isolate the GIP-arm contribution directly — a research question of substantial mechanistic interest.
Why are both molecules in clinical development if retatrutide produces deeper weight loss?
Three reasons. First, the development programs were initiated in parallel before the comparative data was available. Second, regulatory and commercial-positioning considerations differ between developers (Lilly’s portfolio vs Innovent’s China-leading position). Third, the mechanism question is not purely “which is deeper” — the GLP-1/glucagon-only architecture may have a cleaner side-effect profile or different clinical-positioning advantages that depth-of-effect-size alone does not capture.
What’s the dose comparison?
Mazdutide: titrated to 6 mg weekly (Phase 2 top dose). Retatrutide: titrated to 12 mg weekly (Phase 2 top dose). Direct dose comparison is complicated by the different receptor architectures — “milligrams” is not meaningful equivalence when the molecules activate different receptor sets.
How do they compare to CagriSema?
Different approach to the same problem. CagriSema produces deeper-than-monotherapy weight loss via combination (cagrilintide + semaglutide). Mazdutide and retatrutide produce deeper-than-monotherapy weight loss via single-molecule multi-receptor architecture. Both routes are valid; the head-to-head data is not yet available. See: Cagrilintide vs Semaglutide.
Storage protocol?
Lyophilized vials at -20 °C long-term or 2-8 °C as working stock; reconstituted with bacteriostatic water; reconstituted solution at 2-8 °C with use within ~30 days; protect from light; never freeze-thaw.
Bottom line
Mazdutide and retatrutide are both glucagon-arm-containing late-stage incretin compounds. Mazdutide is the GLP-1 / glucagon dual agonist developed primarily through Chinese clinical trials. Retatrutide is the GLP-1 / GIP / glucagon triple agonist with the global TRIUMPH program. The single architectural difference (presence or absence of GIP) produces the deeper retatrutide readout in published Phase 2 data. For research-protocol design, mazdutide is the cleaner dual-agonist option for isolating GLP-1 + glucagon mechanism; retatrutide is the deeper-effect-size molecule for maximum-readout research. See Best peptides for fat loss for full cluster context.
Related research guides
Written by
Sophie ChenPharmaceutical Content Researcher · 8 years experience
Sophie Chen is a pharmaceutical content researcher with 8 years covering generic medication access and clinical pharmacology. She specialises in international regulatory frameworks, bioequivalence standards, and patient-facing education on therapeutic drug classes. She is not a clinician.